515 CRS-207, a mesothelin-targeted immunotherapy, in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). (September 2015) - Hassan, R.; Antonia, S.J.; Alley, E.W.; Kindler, H.L.; Jahan, T.; Grous, J.J.; Honarmand, S.; McDougall, K.; Whiting, C.C.; Nair, N.; Lemmens, E.; Tsujikawa, T.; et al.